Tesamorelin

Overview

Tesamorelin is the only FDA-approved medication for reducing visceral abdominal fat in any patient population. First approved by the FDA in November 2010 for the reduction of excess visceral fat in HIV-infected patients with lipodystrophy, tesamorelin established a distinct therapeutic category: a peptide therapy that does not lower body weight but specifically targets the metabolically dangerous visceral fat depot surrounding internal organs.

As of 2026, tesamorelin retains that unique regulatory position. No other peptide, no other small molecule, and no GLP-1-class drug has FDA-approved labeling for visceral fat reduction as a standalone indication. The updated formulation approved by the FDA in March 2025 simplified reconstitution to weekly (rather than daily) and reduced injection volume by more than half, removing one of the practical adherence barriers that had limited broader use.

In Tennessee, tesamorelin is most commonly prescribed in two patient contexts. First, the on-label indication: adults with HIV who have developed lipodystrophy as a sequela of long-term antiretroviral therapy. Second, off-label use in non-HIV patients with excess visceral adiposity, cardiometabolic risk, or body composition goals — a more controversial application that is not FDA-evaluated for safety or efficacy.

How Tesamorelin Works

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the anterior pituitary to release growth hormone. The native GHRH molecule has a short half-life and is degraded rapidly. Tesamorelin is structurally modified to resist degradation, giving it a longer plasma half-life and enabling once-daily subcutaneous dosing.

At the pituitary, tesamorelin binds GHRH receptors and stimulates the release of endogenous growth hormone (GH). Critically, this is mechanistically different from administering exogenous GH directly. With exogenous GH, the pituitary’s natural pulsatile release pattern is suppressed and the negative feedback loop is bypassed. With tesamorelin, the pituitary continues to release GH in its physiologic pulsatile rhythm and downstream feedback (via IGF-1 and somatostatin) continues to function. This preservation of the natural rhythm is the central pharmacologic argument for GHRH analog therapy over exogenous GH administration.

The increased GH and IGF-1 levels then drive the metabolic effect that is tesamorelin’s clinical hallmark: a selective reduction in visceral adipose tissue. Why visceral fat specifically responds to elevated GH/IGF-1 signaling — while subcutaneous fat is relatively spared — is incompletely understood at the molecular level, but it is the consistent observation across the trial program. Tesamorelin reduces visceral fat without producing meaningful change in subcutaneous fat or lean body mass, and is described in FDA labeling as “weight neutral.”

This is an important framing for patients. Tesamorelin is not a weight-loss drug. It is a body composition drug, and specifically a visceral-fat drug.

Clinical Evidence

Tesamorelin’s FDA approval rests on two pivotal multicenter, randomized, double-blind, placebo-controlled phase 3 trials in patients with HIV-associated lipodystrophy [3]. Study 1 enrolled 412 patients; Study 2 enrolled 404. Each trial consisted of a 26-week Main Phase (active versus placebo) followed by a 26-week Extension Phase (continued therapy or crossover).

The pivotal trials demonstrated significant visceral adipose tissue (VAT) reduction at 26 weeks — mean VAT reduction was approximately 15–18% in the treated arms versus modest or no change with placebo. The VAT benefit was sustained at 52 weeks in patients who continued therapy. Beyond the VAT endpoint, treated patients showed improvements in triglycerides and adiponectin, and in some analyses, modest improvements in markers of hepatic steatosis.

A post hoc analysis published in 2023 [4] examined whether the VAT-reduction effect of tesamorelin was preserved in HIV patients regardless of dorsocervical fat status — a relevant clinical question because dorsocervical fat (“buffalo hump”) is a common feature of HIV lipodystrophy. The analysis found that VAT reduction with tesamorelin was preserved regardless of dorsocervical fat presence.

FDA labeling for tesamorelin explicitly states that the medication is “not indicated for weight loss management” and has a “weight neutral effect” [1]. This is a deliberate and important framing. Across the trial program, total body weight changes were small. The effect is selective on the visceral fat compartment, not on overall body mass.

For off-label use in non-HIV patients — the application many Tennessee clinics see — the evidence base is much thinner. There are some small studies and case series in non-HIV populations with visceral adiposity, but no large randomized trials. Long-term cardiovascular safety in non-HIV populations receiving chronic GHRH analog therapy has not been established. Patients considering off-label tesamorelin should understand that they are stepping outside the FDA-evaluated evidence base.

FDA-Approved Indication and Off-Label Use

The FDA-approved indication is narrow and specific: reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Approved in November 2010, this approval rests on the two pivotal phase 3 trials described above. The March 2025 supplemental approval introduced an updated formulation requiring only weekly reconstitution and using less than half the previous injection volume — a meaningful adherence improvement — but did not change the underlying indication [2].

Off-label use in Tennessee and across the United States has expanded, particularly in functional medicine, cardiometabolic specialty practice, and concierge primary care. The typical off-label use cases are:

• Non-HIV patients with excess visceral adiposity, particularly when waist circumference and imaging suggest disproportionate visceral fat
• Patients with metabolic-associated steatotic liver disease (MASLD) — formerly known as NAFLD — for whom visceral fat reduction is a relevant therapeutic target
• Patients with elevated cardiometabolic risk and central adiposity
• Body composition goals in patients not adequately addressed by GLP-1 therapy or who want a complementary visceral-fat-targeted approach

Off-label prescribing is legal when supported by clinical judgment, but Tennessee patients should clearly understand that:

• The FDA has not evaluated tesamorelin in non-HIV populations
• Long-term cardiovascular safety in non-HIV adults is unknown
• Insurance coverage outside the HIV lipodystrophy indication is generally not available
• Off-label tesamorelin is not a substitute for GLP-1 therapy in patients whose primary goal is overall weight reduction

What to Expect on Tesamorelin Therapy

Patients beginning tesamorelin should expect a structured therapeutic experience with built-in reassessment points and baseline-versus-follow-up monitoring.

Baseline assessment. Most Tennessee clinics will obtain a careful medical history including cancer history (particularly for off-label use), pituitary history, diabetes and glucose status, and pregnancy status. Standard baseline labs typically include IGF-1, HbA1c or fasting glucose, lipid panel, and sometimes a basic metabolic panel. For patients in whom the goal is specifically visceral fat reduction, baseline imaging (CT or MRI of the abdomen) is sometimes obtained to provide an objective measurement of visceral adipose tissue.

Initiation and early weeks. Tesamorelin is initiated at the labeled dose; there is no titration in the way that GLP-1 medications require. Injection technique is reviewed in the first visit. Most patients experience injection site reactions in the first few weeks as their tissue adjusts; rotating injection sites and proper technique minimize this.

Weeks 4 to 8. Patients may begin to notice subtle changes in body composition — reductions in waist circumference, changes in how clothing fits — though scale weight typically remains stable. Joint pain (arthralgia) is most commonly reported in this window and tends to attenuate with continued use. Some patients report improved energy or sleep quality; these are less consistently described than the body composition changes.

Weeks 12 to 26. The principal visceral fat reduction effect is best characterized at 26 weeks based on the trial data. Most patients show meaningful waist circumference reduction by this point if they are responders. Mid-course IGF-1 monitoring (typically at 12 weeks) confirms that levels are within the appropriate physiologic range. Glucose parameters are reassessed.

52 weeks and beyond. Patients who continue therapy through 52 weeks see sustained or further improvement in visceral fat reduction. Long-term continuation decisions are individualized to the patient’s response, tolerability, indication, and cost. There is no defined endpoint at which therapy “completes” in the way an antibiotic course does.

Discontinuation. When tesamorelin is discontinued, the visceral fat reduction effect is not necessarily sustained — patients may regain visceral fat over the subsequent months. Continuation as long-term therapy is the more common framing in the on-label HIV population.

Tesamorelin Dosing Protocol

Per the updated formulation’s FDA-approved labeling, tesamorelin is administered by subcutaneous injection at 1.4 mg or 2 mg daily. The historical daily formulation used 2 mg daily. The newer formulation requires only weekly reconstitution and uses less than half the previous injection volume, simplifying the practical experience of therapy.

Injections are typically given in the abdomen, rotated among sites to minimize injection-site reactions. The daily injection schedule reflects tesamorelin’s pharmacokinetics — a substantial improvement over native GHRH’s minutes-long half-life, but still requiring daily replenishment to maintain effective GHRH receptor stimulation.

A typical clinical course in HIV lipodystrophy is 26 weeks for an initial response assessment, with continued therapy through 52 weeks if VAT reduction is achieved and tolerability is favorable. Off-label courses follow similar reassessment intervals.

Side Effects and Safety

The most commonly reported side effects in the pivotal phase 3 trials were arthralgia (joint pain), injection site reactions, peripheral edema, myalgia, paresthesia, hypoesthesia, and headache. IGF-1 elevations are an expected on-target effect, and most clinicians monitor IGF-1 periodically to ensure levels remain within the appropriate physiologic range.

Glucose intolerance is a concern with any therapy that raises GH and IGF-1, and tesamorelin is no exception. Trials reported transient elevations in fasting glucose and HbA1c in some patients, and current labeling recommends monitoring metabolic parameters at baseline and during therapy.

Long-term cardiovascular safety in non-HIV populations receiving chronic GHRH analog therapy is unknown. The pivotal trials enrolled HIV patients, and the chronic-use safety database is most robust in that population. Off-label use in healthy adults carries an unquantified long-term safety risk that patients should discuss honestly with their provider.

Contraindications

Tesamorelin is contraindicated in patients with:

• Active malignancy (theoretical concern from elevated IGF-1 signaling)
• Pregnancy (Category X)
• Known hypersensitivity to tesamorelin or to mannitol
• Disrupted hypothalamic-pituitary axis from pituitary surgery, hypopituitarism, severe head trauma, or head and neck radiation
• Concurrent systemic corticosteroid use (interferes with the GH axis)

Caution is warranted in patients with active or proliferative diabetic retinopathy and in those with significant pre-existing glucose dysregulation.

Monitoring on Tesamorelin

Standard monitoring during tesamorelin therapy includes:

• IGF-1. Baseline and periodic measurement (typically every 12 to 26 weeks) to confirm levels remain within the appropriate physiologic range. Excessive IGF-1 elevation suggests over-stimulation of the GH axis and may warrant dose adjustment.
• Glucose and HbA1c. Baseline and periodic reassessment to monitor for the glucose intolerance that can occur with chronic GH-axis stimulation.
• Lipid panel. Baseline and follow-up to track the triglyceride improvements that are expected on therapy.
• Imaging. Where the indication is visceral fat reduction specifically, baseline and 26- or 52-week CT or MRI is sometimes obtained as an objective measure of response.
• Symptom check. Periodic review of joint pain, peripheral edema, injection site reactions, and overall tolerability.

Some clinics include thyroid function and cortisol monitoring as part of a broader hormone optimization workup, particularly for patients on off-label protocols layered with other peptides.

Sourcing and Quality Considerations

Tesamorelin is one of the more expensive peptide therapies, and the sourcing landscape includes both brand-name FDA-approved product and 503A-compounded versions. Tennessee patients should clarify with their clinic:

• Is the dispensed product the brand-name FDA-approved formulation or a 503A-compounded version?
• If compounded, which licensed pharmacy is the source, and what batch testing is performed?
• Brand-name product carries the assurance of FDA-evaluated manufacturing; compounded versions vary by pharmacy quality.
• Insurance coverage, if applicable, is typically only available for brand-name product in the FDA-approved HIV indication.

Patients pursuing off-label use should also clarify the total cost of therapy upfront — medication, clinic visits, monitoring labs, and any imaging — because a tesamorelin course is a substantial financial commitment.

Tesamorelin vs Other Growth Hormone Peptides

Tesamorelin sits within a broader family of peptides that work on the growth hormone axis. Patients researching options often want to understand how it compares to the other commonly-discussed agents.

Versus sermorelin. Both are GHRH analogs. Sermorelin is shorter-acting and weaker at the receptor than tesamorelin, and is no longer marketed as an FDA-approved branded product — it is available through 503A compounding pharmacies. Tesamorelin is more potent, has a longer half-life, has current FDA approval (for the HIV indication), and produces more substantial visceral fat reduction. Tesamorelin is also substantially more expensive.

Versus CJC-1295. CJC-1295 is also a modified GHRH analog. The “with DAC” version of CJC-1295 has a half-life of approximately 6–8 days due to albumin binding, giving it a much longer duration of action than tesamorelin. CJC-1295 is not FDA-approved. The no-DAC version of CJC-1295 has a short half-life and is closer in profile to native GHRH pulsatility. Tesamorelin has the FDA-approval advantage; CJC-1295 has dosing-frequency convenience for some protocols.

Versus ipamorelin. Ipamorelin is a growth hormone secretagogue (GHRP) and works on a different receptor — the ghrelin/growth hormone secretagogue receptor — rather than the GHRH receptor. The two are complementary rather than directly comparable, and the GHRH-analog plus GHRP combination is a common protocol in clinical practice. Ipamorelin is not FDA-approved.

Tesamorelin’s distinguishing feature within this family is its current FDA approval and its specific evidence for visceral fat reduction. None of the other GHRH analogs or GHRPs has comparable trial-grade evidence for the visceral fat outcome.

Cost and Insurance Considerations

Tesamorelin is one of the more expensive peptide therapies in clinical practice, and the cost structure matters meaningfully for patients considering therapy.

Brand-name FDA-approved product carries the highest acquisition cost. Cash pricing can run several thousand dollars per month depending on dose and pharmacy. Insurance coverage is typically only available for the FDA-approved HIV-associated lipodystrophy indication; prior authorization and specialty pharmacy dispensing are typical for covered patients.

503A-compounded versions are typically less expensive but are not eligible for insurance coverage and may vary by pharmacy quality. Patients accessing tesamorelin through compounding should verify pharmacy licensure and batch testing.

Off-label cash-pay use is the typical pathway for non-HIV patients. Tennessee patients pursuing off-label use should clarify upfront the total cost including medication, clinic visits, baseline and follow-up labs, and any imaging. A 26-week course represents a substantial financial commitment, and patients should be clear-eyed about this before initiation.

Insurance billing for off-label use is generally not viable. Insurers typically do not cover off-label peptide use, and patients should not assume that the FDA approval for the HIV indication will translate to coverage for other applications.

Finding a Tesamorelin Provider in Tennessee

Tesamorelin is offered by a more limited set of Tennessee clinics than peptides like BPC-157 or ipamorelin, primarily because of its cost, the specificity of its on-label indication, and the relative scarcity of providers comfortable with off-label use in non-HIV patients. In Nashville and the Middle Tennessee corridor (Franklin, Brentwood, Murfreesboro), tesamorelin is available through cardiometabolic specialty practices, HIV-focused infectious disease clinics, and some functional medicine practices. Knoxville, Chattanooga, and Memphis each have providers with tesamorelin experience.

Key questions to ask a Tennessee provider:

• For which indication are you prescribing tesamorelin in my case — the FDA-approved HIV indication, or off-label?
• If off-label, what is the rationale, and what monitoring will we use to assess response?
• Is the medication brand-name FDA-approved product, or compounded? What is the source?
• What IGF-1, glucose, and lipid monitoring schedule do you use?
• What is the total cost — medication, visits, and labs — over a 26-week course?
• What is the plan if I don’t show an adequate response at 26 weeks?

Clinics that answer these questions clearly and that frame the off-label evidence base honestly are generally the right ones to work with.

References

1. U.S. Food and Drug Administration. Tesamorelin prescribing information. Initial approval November 2010.
2. U.S. Food and Drug Administration. Supplemental Biologics License Application approval for updated weekly-reconstitution formulation. March 25, 2025.
3. Falutz J, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. JAIDS. 2013.
4. Post hoc analysis: Effect of tesamorelin in people with HIV with and without dorsocervical fat. 2023.